PRIA Logo™
119-s-3751119th Congress

Prescription Drug Supply Chain Pricing Transparency Act

Sponsored By: Senator Bennet, Michael F. [D-CO]

Introduced

Summary

This bill would require the Government Accountability Office to study how price-related compensation structures operate across the retail prescription drug supply chain. It aims to map who gets fees tied to a drug's price and how those payments could affect drug selection and distribution.

Show full summary
  • Congress and oversight bodies would receive a comprehensive GAO report with recommendations within 2 years.
  • Pharmacy benefit managers, Part D plan sponsors, drug wholesalers, pharmacies, manufacturers, pharmacy services administrative organizations, brokers, auditors, consultants, rebate aggregators, and other service providers would be examined for the types, magnitudes, and prevalence of price-linked fees.
  • The study would cover business models, differences between affiliated and unaffiliated entities, potential conflicts of interest such as percentage-based fees that could favor higher-priced drugs, trends over time, and comparisons across market segments like Medicare Part D and Medicaid.

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

No Economic Impacts Identified for this Bill

Sponsors & CoSponsors

Sponsor

Bennet, Michael F. [D-CO]

CO • D

Cosponsors

  • Sen. Lankford, James [R-OK]

    OK • R

    Sponsored 1/29/2026

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation